Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice.

I Aguilera GarcíaR M García MorenoB López PlazaB Barquiel AlcaláP Vázquez PérezA C Barreda BonisE Zamarrón de LucasS Palma MillaM C Prados SánchezN González Pérez de Villar

Published in: Diabetes research and clinical practice (2024)

ETI therapy impacted CFRD in clinical practice reducing insulin needs and improving glycemic control measured by HbA1c and CGM. The improvements can be observed from the first 3 months of treatment.

Keyphrases

glycemic control
clinical practice
type diabetes
cystic fibrosis
blood glucose
insulin resistance
pseudomonas aeruginosa
cardiovascular disease
transcription factor
stem cells
chronic obstructive pulmonary disease
replacement therapy
bone marrow
cell therapy
air pollution